A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...